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Abstract
Background: The Rotavirus Efficacy and Safety Trial was a placebo-controlled Phase III study that evaluated the safety 
and efficacy of a three-dose pentavalent rotavirus vaccine (RV5) including its effect on healthcare utilization for 
rotavirus gastroenteritis (RVGE). The per-protocol (PP) analyses, which counted events occurring 14 days after dose 3 
among infants without protocol violations, have already been published. This paper evaluates the consistency of the 
healthcare utilization results based on the modified intention to treat (MITT) analyses with the PP analyses. The MITT 
analyses include all infants receiving at least one dose of vaccine or placebo and follow-up begins after dose 1. The 
paper also explores the consistency of the results for different subgroups of the study population with different types 
of surveillance.
Methods: Data on healthcare utilization for acute gastroenteritis were collected via telephone interviews after 
administration of the first dose. Parents were either contacted every 6 weeks or every 2 weeks depending on the 
substudy in which they were enrolled. Those contacted every 2 weeks were also asked to complete symptom diaries. 
Poisson regression was used to evaluate the effect of RV5 on the rates of RVGE-associated healthcare encounters in all 
of the analyses.
Results: In the first 2 years after vaccination, RV5 reduced the combined rate of hospitalizations and emergency 
department (ED) visits 88.9% (95% CI: 84.9, 91.9) for all RVGE regardless of serotype in the MITT analysis compared with 
a 94.5% (95% CI: 91.2, 96.6) reduction based on the G1-G4 PP analysis. By type of surveillance, the rate reductions for 
the G1-G4 PP analysis were 91.0% (95% CI: 81.7, 95.5) and 95.9% (95% CI: 92.2, 97.8) among parents contacted every 2 
weeks (number evaluable = 4,451) and every 6 weeks (number evaluable = 52,683) respectively.
Conclusions: Our analyses demonstrated that the effect of RV5 on reducing the rate of hospitalizations and ED visits 
based on the MITT analyses were generally consistent with the PP analyses. The rate of events for subgroups with 
different intensities of surveillance differed but the effect of RV5 on the relative rate reductions were consistent with 
the results that have already been published.
Trial Registration: ClinicalTrials.gov number, NCT00090233
Background
Prior to the introduction of rotavirus vaccines, rotavirus
gastroenteritis (RVGE) was the most common cause of
severe gastroenteritis in infants and young children.
Almost every child has been infected with rotavirus by 5
years of age in both developing and industrialized coun-
tries [1]. Rotavirus-positive acute gastroenteritis is more
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Page 2 of 14severe than rotavirus-negative acute gastroenteritis with
higher rates of dehydration, vomiting, fever, and signs of
lethargy [2]. There are nearly 600,000 deaths due to
RVGE worldwide which mainly occur in developing
countries [1]. In industrialized countries, hospitalization
rates had been high prior to the introduction of vaccina-
tion programs [3]. Children are usually admitted to the
hospital to prevent or treat dehydration [4-6]. RVGE
most often occurs at specific times of the year [7]. In the
United States, for example, rotavirus activity follows a
distinct winter-spring seasonal pattern [8].
Two rotavirus vaccines are currently being marketed in
various countries throughout the world to prevent RVGE.
One is a monovalent G1P1A[8] human rotavirus vaccine
(RV1; Rotarix®, GlaxoSmithKline Biologicals, Rixensart,
Belgium). The other is a pentavalent (G1, G2, G3, G4,
P1A[8]) human bovine (WC3 strain) reassortant rotavi-
rus vaccine (RV5; RotaTeq®, Merck & Co., Inc., White-
house Station, NJ, USA) [9]. Both vaccines were found to
be safe and efficacious in large studies powered to detect
intussusception risk [10-13]. Both vaccines have also
been recommended for routine immunization in the U.S.
as well as several countries in Latin America, Europe, and
Australia [14].
Since RV5 was included in the immunization schedule
in the U.S., surveillance studies have been conducted to
evaluate vaccine effectiveness. In a national sentinel net-
work of laboratories, the median length of the rotavirus
season decreased by 54%, the number of stool specimens
submitted for testing decreased by 67%, and the propor-
tion of test results positive for rotavirus declined by 69%
after vaccination in the 2007-8 season compared to the
2000-2006 seasons [15]. Similar results were reported at
Children's Hospital of Philadelphia [16]. In the 2007-8
seasons, there was an 87% decline in community acquired
rotavirus cases compared to the same time period in
2005-2006. Other studies reported sharp reductions in
rotavirus-related hospitalizations and emergency depart-
ment (ED) visits after RV5 became available even among
age groups that would not have been eligible to receive
the vaccine [17-19]. These reductions in healthcare utili-
zation parallel what was observed in the Phase III trial.
The efficacy and safety of RV5 was evaluated in the
Rotavirus Efficacy and Safety Trial (REST), a large inter-
national placebo-controlled, blinded trial conducted from
2001 to 2005 with nearly 70,000 healthy infants enrolled
from 11 countries. Infants were to receive three doses of
either RV5 or placebo. The large sample size and the
length of follow-up in REST provided a unique opportu-
nity to quantify the effect of RV5 on healthcare outcomes
related to RVGE in a prelicensure study. In the per-proto-
col (PP) analysis, which was comprised of infants without
protocol violations and counted events occurring 14 days
after dose 3, RV5 reduced the rate of hospitalizations and
ED visits related to G1-G4 RVGE by 94.5% (95% CI: 91.2 -
96.6) in the first two years after vaccination [10]. The rate
reductions were generally consistent among study popu-
lations across three regions - the US (including the
Navajo and White Mountain Apache Nations), Europe,
and Latin America [20].
The efficacy reported in clinical trials can not always be
directly extrapolated to other populations because of the
strict inclusion criteria for enrollment as well as the close
monitoring of subjects in the trial [21,22], especially
when the results are based on a PP analysis. This paper
assesses the robustness of the previously published
RVGE-associated healthcare utilization results from
REST based on the PP analysis by evaluating the reduc-
tion in RVGE-associated healthcare utilization regardless
of serotype in a modified intention-to-treat (MITT) anal-
ysis among infants receiving at least one dose of vaccine.
The method and frequency of surveillance also differed
for specific subgroups within the study population. The
effects of the differences in intensity of surveillance on
healthcare utilization rates were also explored.
Methods
Study design and case definitions
In REST, infants were randomly assigned in a 1:1 ratio to
receive either vaccine or visibly indistinguishable placebo
starting at 6-12 weeks of age, followed by two more doses
at 4-10 week intervals up to 32 weeks of age [10,20].
Doses were administered year-round without regard to
RV seasonality. The case definition for acute gastroen-
teritis (AGE) was 3 or more watery or looser-than-nor-
mal stools within a 24-hour period and/or forceful
vomiting along with the identification of rotavirus by
enzyme immunoassay (EIA) in a stool specimen taken
within 14 days after the onset of symptoms. G-serotypes
were identified by one-step reverse-transcriptase-poly-
merase chain reaction (PCR) amplification followed by
sequencing [23]. More complete detail about the study
design and the methods used to analyze the data were
provided in the earlier publications [10,20]. The protocol
was approved by the ethical review committee at each site
and conducted in conformance with applicable country
or local requirements. All guardians signed informed
consent prior to vaccination.
PP vs. MITT analyses
Earlier publications have presented the PP analyses for
the effect of RV5 on reducing the rates of hospitalizations
and/or ED visits for the overall study population as well
as the rate reductions by region and serotype for the first
two years after vaccination. The analyses for the overall
study population and the analyses stratified by region
were based on the G1, G2, G3, and G4 serotypes included
in RV5. The effect of RV5 on hospitalizations and ED vis-
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the 5 most common G-serotypes circulating in Europe
and the Americas: G1, G2, G3, G4 and G9.
For the analyses stratified by region, three separate
regions were examined: the US including the Navajo and
White Mountain Apache Nations (but not Puerto Rico),
Europe, and Latin America or the Caribbean including
the Commonwealth of Puerto Rico [20]. Although a self-
governing island that is part of the commonwealth of the
United States, Puerto Rico was included in the Latin
American/Caribbean region for these analyses because of
its close proximity to the Caribbean.
In this paper we compare the G1-G4 PP analyses with
the MITT analyses regardless of serotype based on
infants receiving at least one dose of vaccine or placebo
where all healthcare encounters anytime after the first
dose are counted for the first two years after vaccination.
The analyses for the overall study population as well as
the analyses stratified by region include all episodes of
RVGE identified by EIA regardless of G-serotypes includ-
ing episodes where rotavirus antigen was detected by
enzyme immunoassay but the serotype could not be
determined by PCR. Table 1 provides a detailed compari-
son of the inclusion criteria for the PP and MITT analy-
ses. Other variations of the PP and MITT analyses were
also presented in order to assess the potential effect of
including all RVGE serotypes, subjects with protocol vio-
lations, and the protection prior to completion of the vac-
cine regimen for the overall study population.
Method and frequency of surveillance
Several substudies were nested within REST. The surveil-
lance method and the frequency of contact with parents
differed between the Clinical Efficacy substudy and the
remainder of the REST cohort. Data on healthcare out-
comes was collected via telephone interviews with par-
ents for all infants. Parents were contacted on days 7, 14,
and 42 after each dose. The parents of infants in the Clin-
ical Efficacy substudy were then contacted every two
weeks until their children completed the study whereas
the parents of the infants not in the substudy were con-
tacted every 6 weeks. Health Care Utilization Question-
naires were completed by study personnel during the
interviews. For infants participating at sites included in
the substudy, all episodes of AGE were reported and par-
ents completed a daily Acute Gastroenteritis Report Card
which permitted an assessment of the severity of each
acute gastroenteritis episode. For infants not included in
the Clinical Efficacy substudy, only hospitalizations and
ED visits associated with episodes of AGE were reported
and no diary cards were completed. This paper also
explores how the intensity of surveillance affected the
reported rates of healthcare encounters for RVGE and the
observed relative reduction in the rate of RVGE health-
care encounters by comparing the results at study sites
included in the Clinical Efficacy substudy with all other
sites.
Given that there were some AGE episodes where stool
specimens were not collected, all AGE episodes were also
analyzed to determine whether any differences between
the two subgroups with respect to AGE/RVGE between
subjects enrolled in the Clinical Efficacy substudy and
other subjects in REST were due to differences in the
rates of healthcare encounters for AGE reported or differ-
ences in the ability to collect stool specimens and confirm
whether the encounters were associated with RVGE.
Statistical analyses
Poisson regression was used to compare the rates of
healthcare encounters in the vaccine and placebo groups.
For the analyses based on the overall study population
and by serotype [10], generalized estimating equations
(GEE) were used to adjust the standard errors and
account for correlations between observations [24,25].
GEE is not optimal when the count of events is small [26].
However, because this methodology was applied to the
serotype specific PP analyses in an earlier publication, it
is applied here to the MITT analyses to be consistent.
GEE also cannot be used when there are no healthcare
encounters in the vaccine or placebo groups. Therefore,
the exact binomial method for ratios of Poisson counts
was used for the analyses stratified by region as well as for
analyses where there was a zero count in one of the
groups being compared. The rates of healthcare encoun-
ters were expressed as the annual number of encounters
per 1000 person-years because the length of follow-up
differed among infants enrolled in the study. All infants
were to be followed for at least 42 days after the last vacci-
nation and up to 365 days after the first dose or until the
end of the study, whichever came first. A subset of infants
in the Clinical Efficacy substudy enrolled during a rotavi-
rus season was followed until the end of the next rotavi-
rus season which resulted in follow-up for time periods
for a maximum of 2 years for some infants.
Results
Infants included in the MITT and PP analyses
Data for 69,274 randomly assigned infants were available
in the REST clinical database at the time the Data and
Safety Monitoring Board determined that the study had
satisfied its criterion for stopping enrollment associated
with the primary safety endpoint assessing the risk of
intussception among vaccine recipients. After that date,
an additional 1027 infants were only followed for safety
but not efficacy. In total, 68,038 infants received at least
one dose of vaccine or placebo including 5,673 vaccinated
infants in the efficacy substudy (Figure 1). The PP analy-
ses included 28,646 evaluable infants in the RV5 group
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were 9,518 infants (4,740 RV5; 4,778 Placebo) with proto-
col violations and 8,773 infants (4,367 RV5; 4,406 Pla-
cebo) violated the protocol because they did not receive
all 3 doses.
The MITT analysis included 33,163 evaluable infants in
the RV5 group and 33,015 evaluable infants in the pla-
cebo group. The MITT analysis differed from a strict
intention-to-treat (ITT) population because it excluded
infants who were randomized but never vaccinated since
these infants were not followed for efficacy outcomes.
Figure 2 accounts for all of the infants excluded from the
MITT analysis in the RV5 and placebo groups with the
reasons for exclusion. Only 1.8% of the infants random-
ized were excluded from the MITT analysis because they
were never vaccinated. Of the 1,860 infants receiving at
least one dose of vaccine or placebo excluded from the
MITT analysis, 92.3% reported an episode of acute gas-
troenteritis but either no stool specimens were collected
to determine whether they were positive for rotavirus or
the stool specimens were collected outside the allowed
time period. Table 2 provides a comparison of the base-
line characteristics for age, race, and gender based on the
Table 1: Comparison of Inclusion/Exclusion Criteria for the Per- Protocol (PP) and Modified Intention-to-Treat (MITT) 
Analyses
Criteria for Comparison PP Analysis MITT Analysis
Infants Randomized but Not Vaccinateda Excluded Excluded
Infants without Follow-up Excludes infants where the end of follow 
up occurs before 14 days after dose 3
Excludes infants where the end of follow up 
is the same day as the first vaccinationa
Infants classified as not-evaluable (Infants 
are classified as not-evaluable if they have 
one or more episodes not-evaluable for 
rotavirus and no episodes positive for 
rotavirus)
Episodes were classified as not-evaluable 
if the stool specimen was positive for 
wild-type rotavirus prior to 14 days after 
dose 3, if there was incomplete clinical 
and/or laboratory results, or the stool 
specimen was collected outside the 14 
day range after symptom onset
Episodes were classified as not-evaluable if 
the clinical and/or laboratory results were 
incomplete or the stool specimen was 
collected outside the 14 day range after 
symptom onset
Infants with protocol violations Excluded Included
Serotypes Overall analysis was limited to RVGE due 
to G1-G4 serotypes
Overall analysis included all RVGE 
regardless of serotype
a There were no healthcare encounters on the day of the first vaccination.
Figure 1 REST Study Design with Respect to the Collection of the 
Healthcare Utilization Data. N = number vaccinated.
 
Large-Scale Cohort
N=68,038
(34,035V:34,003P)
• Efficacy against hospitalizations 
and emergency department visits 
for rotavirus acute gastroenteritis 
(RVGE)
• Efficacy against all RVGE 
• Efficacy against office visits
for RV AGE (REST)
Clinical Efficacy 
Substudy
N=5,673
(2,834V:2,839P)
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and the MITT analysis regardless of serotype.
Comparison of results based on PP analysis for serotypes 
G1-G4 and PP analysis regardless of serotype for overall 
study population
There were 389 hospitalizations and emergency depart-
ment (ED) visits (20 RV5; 369 Placebo) in the PP analysis
limited to the G1-G4 serotypes (Table 3). When all epi-
sodes of rotavirus gastroenteritis regardless of serotype
were included in the PP analysis (with follow-up begin-
ning 14 days after administration of the third dose), there
were 429 hospitalizations and ED visits (22 RV5, 407 P -
data not shown in tables) and RV5 reduced the rate of
hospitalizations and ED visits for the first 2 years after
vaccination by 94.6% (95% CI: 91.5, 96.5) for the PP analy-
sis regardless of serotype compared with a 94.5% (95% CI:
91.2, 96.6) rate reduction based on the PP analysis for the
G1-G4 serotypes. In addition to the 389 hospitalizations
and ED visits included in the PP analysis limited to the
G1-G4 serotypes, the PP analysis regardless of serotype
also included 14 (0 RV5, 14 P) hospitalizations and ED
visits associated with the G9 serotype, 1 ED visit associ-
ated with the G12 serotype, and 25 (2 RV5, 23 P) hospital-
izations and ED visits where the serotype could not be
identified by PCR.
Comparison of results based on PP analysis regardless of 
serotype and MITT analysis regardless of serotype for 
overall study population
When all episodes of rotavirus regardless of serotype
were included and follow-up began after administration
of the first dose of RV5 or placebo in the MITT analysis,
there were 580 (58 RV5, 522 P) hospitalizations and ED
visits included. RV5 reduced the rate of hospitalizations
and ED visits by 88.9% (95% CI: 84.9, 91.9). There were
151 additional hospitalizations and ED visits in the MITT
analysis compared with the PP analysis regardless of sero-
type. Of this total, 43 hospitalizations and ED visits (14
RV5, 29 Placebo) occurred among protocol violators and
107 hospitalizations and ED visits (21 RV5, 86 Placebo)
occurred prior to 14 days after dose 3 of which 22 hospi-
talizations and ED visits (12 RV5, 10 Placebo) occurred
within the 13 days after receiving the first dose. There
was also one additional ED visit that occurred more than
14 days after dose 3 in an RV5 recipient classified as not
evaluable in the PP analysis. If the MITT analysis
excluded protocol violators, the reduction in the rate of
hospitalizations and emergency department visits associ-
ated with RV5 would be 91.0% (95% CI: 87.3, 93.5 - data
not shown in tables). If the MITT analysis excluded pro-
tocol violators and only counted RVGE-related hospital-
izations and ED visits beginning 14 days after dose 1, the
Figure 2 Subject Accounting for MITT Analyses. There were no health care encounters on the first day of vaccination among 26 infants without 
follow-up after the first day of vaccination.
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MITT analysis (n=33015)
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ot
Randomized but not vaccinated   
(n=627)
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Table 2: Comparison of Baseline Characteristics for PP and MITT Analyses based on the Number of Evaluable Subjects
PP Analysis MITT Analysis
RV5 Placebo RV5 Placebo
Infants vaccinated 34035 34003 34035 34003
Protocol violatorsa 4740 4778 **** ****
Infants with no follow-upb 26 25 10 13
Infants classified as not-evaluable 623 712 862 975
Infants contributing to the analysis 28646 28488 33163 33015
Age at Entry - in weeks
Mean 9.8 9.8 9.8 9.8
Median 10 10 10 10
Range (6-13) (6-13) (6-13) (6-13)
Race - number, %
White 20676 (72.2%) 20653 (72.5%) 23021 (69.4%) 22912 (69.4%)
Black 2230 (7.8%) 2215 (7.8%) 2739 (8.3%) 2761 (8.4%)
Hispanic 3644 (12.7%) 3552 (12.5%) 4721 (14.2%) 4656 (14.1%)
Other 2096 (7.3%) 2068 (7.2%) 2682 (8.1%) 2686 (8.1%)
Gender - number, %
Female 14112 (49.3%) 14131 (49.6%) 16343 (49.3%) 16331 (49.5%)
Male 14534 (50.7%) 14357 
(50.4%)
16820 (50.7%) 16684 
(50.5%)
a Subjects who received a vial where a temperature excursion occurred, subjects who had less than 3 vaccinations or less than 28 days 
between vaccinations, and subjects who were cross-treated or prematurely unblinded.
b In the PP analysis follow-up begins 14 days after dose 3; in the MITT analysis follow-up begins after dose 1
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Table 3: Comparison of PP and MITT Analyses for RVGE Healthcare Encounters by Type of Encounter
PP Analysis MITT Analysis
RV5 Placebo % Rate Reduction
(95% CI)
RV5 Placebo % Rate Reduction
(95% CI)
Hospitalizations and ED Visits
Infants vaccinated 34035 34003 34035 34003
Protocol violatorsa 4740 4778 **** ****
Infants with no follow-upb 26 25 10 13
Infants classified as not-evaluable 623 712 862 975
Infants contributing to the analysis 28646 28488 33163 33015
No. (rate) of hospitalizations & ED visitsc 20 (1.1) 369 (20.6) 94.5
(91.2, 96.6)
58 (2.0) 522 (18.4) 88.9
(84.9, 91.9)
No. (rate) of hospitalizationsc 6 (0.3) 144 (8.0) 95.8
(90.5, 98.2)
16 (0.6) 215 (7.6) 92.6
(87.3, 95.7)
No. (rate) of ED visitsc 14 (0.8) 225 (12.6) 93.7
(88.8, 96.5)
42 (1.5) 307 (10.8) 86.4
(80.2, 90.6)
Office Visits
Infants vaccinated 2834 2839 2834 2839
Protocol violatorsa 295 271 **** ****
Infants with no follow-upb 11 6 2 4
Infants classified as not-evaluable 355 284 429 403
Infants contributing to the analysis 2173 2278 2403 2432
No. (rate) of office visitsc 13 (5.5) 98 (39.7) 86.0
(73.9, 92.5)
21(6.6) 123 (38.0) 82.6
(71.6, 89.3)
a Subjects who received a vial where a temperature excursion occurred, subjects who had less than 3 vaccinations or less than 28 days between vaccinations, and subjects who were cross-treated 
or prematurely unblinded
b In the PP analysis follow-up begins 14 days after dose 3; in the MITT analysis follow-up begins after dose 1
c The RV5 and Placebo columns represent the number (rate) of events; the rates reflect the incidence density expressed as the annual number of events
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not shown in tables).
Comparison of PP and MITT analyses stratified by serotype
The effect of RV5 on the rate of RVGE hospitalizations
and ED visits combined for each of 5 common serotypes
currently circulating in the Americas and Europe identi-
fied during REST are shown for the MITT and PP analy-
ses in Table 4. Compared with the PP analysis, the
number of hospitalizations and ED visits in the MITT
analysis increased by 102 (16 RV5, 86 P) for the G1 sero-
type, 4 (0 RV5, 4 P) for the G2 serotype, 7 (2 RV5, 5 P) for
the G3 serotype, 2 (0 RV5, 2 P) for the G4 serotype, and
13 (2 RV5, 11 P) for the G9 serotype. The rate reduction
for the G2 serotype, 87.6% (95% CI: <0, 98.5) was not sta-
tistically significant for the PP analysis. However, the
91.7% (95% CI: 34.7, 99.0) rate reduction reflected better
sensitivity of the MITT analysis to the difference between
RV5 and placebo for G2. The rate reductions for the G1,
G3, G4 and G9 serotypes were statistically significant
based on both the PP and MITT analyses. By serotype,
the rate reductions were 95.1% (95% CI: 91.6, 97.1) for
G1, 93.4% (95% CI: 49.4, 99.1) for G3, 89.1% (95% CI:
52.0, 97.5) for G4, and 100% (95% CI: 69.6, 100) for G9
based on the PP analysis and 92.3% (95% CI: 88.2, 95.0)
for G1, 85.1% (95% CI: 49.6, 95.6) for G3, 90.1% (95% CI:
57.2, 97.7) for G4, and 92.1% (95% CI: 66.1, 98.2) for G9
based on the MITT analysis.
Comparison of G1-G4 PP analysis and MITT analysis 
regardless of serotype stratified by region
Table 5 presents the effect of RV5 on the rates of RVGE
healthcare encounters for the G1-G4 PP analysis and the
MITT analysis regardless of serotype stratified by region.
Based on the G1-G4 PP analysis, use of RV5 resulted in
the following reductions in the rate of hospitalizations
and ED visits: 94.7% (95% CI: 90.9, 96.9) for Europe,
94.9% (95% CI: 84.0, 98.9) for the US, and 90.0% (95% CI:
29.4, 99.8) for Latin America and the Caribbean. By com-
parison, use of RV5 resulted in the following reductions
in the rate of hospitalizations and ED visits for the MITT
analysis regardless of serotype: 92.0% (95% CI: 88.4, 94.6)
for Europe, 80.0% (95% CI: 68.7, 87.6) for the US, and
80.2% (95% CI: 28.5, 96.2) for Latin America and the
Caribbean. In the US, the difference in the rate reduc-
tions for the G1-G4 PP analysis and the MITT analysis
regardless of serotype was more pronounced for ED vis-
its. The rate reductions for ED visits were 92.9% (95% CI:
77.4 - 98.6) based on the G1-G4 PP analysis compared
with a corresponding 71.6% (95% CI: 54.3 - 82.9) rate
reduction based on the MITT analysis regardless of sero-
type. The rate reductions for hospitalizations were 100%
(95% CI: 73.8, 100) based on the G1-G4 PP analysis com-
pared with 97.4% (95% CI: 84.8, 99.9) based on the MITT
analysis regardless of serotype.
Comparison of results for RVGE and AGE health care 
encounters by intensity of surveillance for PP analysis
Table 6 presents the effect of RV5 on the rates of hospital-
izations and ED visits for RVGE and AGE as well as the
number and rate of events (annual number of events per
1000 person years) among infants in the RV5 and placebo
groups for the PP analysis stratified by the intensity of
surveillance at the study site. There were 4,451 infants in
the Clinical Efficacy substudy (2,173 RV5; 2,278 Placebo)
and the remaining 52,683 infants were participating at
other sites (26,473 RV5; 26,210 Placebo - numbers not
shown in tables). The relative reduction in the rate of hos-
pitalizations and emergency department visits for RVGE
and AGE in the Clinical Efficacy substudy were generally
consistent with the rate reductions at other sites. By type
of surveillance, the rate reductions were 91.0% (95% CI:
81.7, 95.5) for the G1-G4 PP analysis and 39.7% (95% CI:
28.0, 49.5) for all AGE among parents contacted every 2
weeks compared with 95.9% (95% CI: 92.2, 97.8) for the
G1-G4 PP analysis and 41.2% (95% CI: 35.0, 46.8) for all
AGE among parents contacted every 6 weeks. However,
the rate of G1-G4 RVGE hospitalizations and ED visits
reported among infants in the placebo group in the Clini-
cal Efficacy substudy (51.8 per 1000 person years) was
more than three times the rate for placebo recipients not
in the substudy (15.6 per 1000 person years). The differ-
ence in the rates for ED visits was more pronounced than
the differences in the rates for hospitalizations. Similarly,
the rate of hospitalizations and ED visits for AGE
reported among infants in the placebo group in the Clini-
cal Efficacy substudy (131.4 per 1000 person years) was
nearly 1.5 times higher than the rate among infants for
RVGE in the placebo group for infants not in the Clinical
Efficacy substudy (53.8 per 1000 person years).
Discussion
The results for REST presented here demonstrate that the
reduction in the rates of hospitalizations and ED visits
associated with the use of RV5 remained very high in the
MITT analysis regardless of serotype despite small differ-
ences between the G1-G4 PP analysis and the MITT
analysis regardless of serotype. The MITT analysis was
more inclusive than the PP analysis because it included
protocol violators, and RVGE episodes regardless of sero-
type immediately following dose 1. Of the 69,274 ran-
domized infants enrolled in REST, only 3,096 (4.5%) were
excluded from the MITT analysis of whom 1481 were in
the vaccine group and 1615 were in the placebo group.
Among those excluded who received at least one dose of
vaccine, the majority did not have stool specimens col-
lected to determine whether the episodes were attribut-
Itzler et al. BMC Pediatrics 2010, 10:42
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Table 4: Comparison of PP and MITT Analyses for RVGE Hospitalizations and Emergency Department (ED) Visits by 
Serotype
PP Analysis MITT Analysis
RV5 Placebo % Rate Reduction
(95% CI)
RV5 Placebo % Rate Reduction
(95% CI)
Infants vaccinated 34035 34003 34035 34003
Protocol violatorsa 4740 4778 **** *****
Infants with no follow-upb 26 25 10 13
Infants classified as not-
evaluable
G1 624 721 889 1006
G2 628 734 904 1050
G3 629 740 903 1062
G4 629 740 905 1063
G9 629 741 905 1065
Infants contributing to the 
analysis
G1 28645 28479 33136 32984
G2 28641 28466 33121 32940
G3 28640 28460 33122 32928
G4 28640 28460 33120 32927
G9 28640 28459 33120 32925
Resultsc
G1 16 (0.9) 328 (18.3) 95.1 (91.6, 97.1) 32 (1.1) 414 (14.6) 92.3 (88.2, 95.0)
G2 1 (0.1) 8 (0.4) 87.6 (<0, 98.5) 1 (0.0) 12 (0.4) 91.7 (34.7, 99.0)
G3 1 (0.1) 15 (0.8) 93.4 (49.4, 99.1) 3 (0.1) 20 (0.7) 85.1 (49.6, 95.6)
G4 2 (0.1) 18 (1.0) 89.1 (52.0, 97.5) 2 (0.1) 20 (0.7) 90.1 (57.2, 97.7)
G9d 0 (0.0) 14 (0.8) 100 (69.6, 100) 2 (0.1) 25 (0.9) 92.1 (66.1, 98.2)
a Subjects who received a vial where a temperature excursion occurred, subjects who had less than 3 vaccinations or less than 28 days between 
vaccinations, and subjects who were cross-treated or prematurely unblinded
b In the PP analysis follow-up begins 14 days after dose 3; in the MITT analysis follow-up begins after dose 1
c The numbers in the RV5 and Placebo columns represent the number (rate) of events; the rates reflect the incidence density expressed as the 
annual number of events per 1000 person-years
d The number of hospitalizations and ED visits among placebo recipients for the per-protocol population has been revised since the NEJM 
publication. One additional healthcare encounter in the placebo group was identified after the NEJM publication [10]
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Table 5: Comparison of PP and MITT Analyses for RVGE Healthcare Encounters by Type of Encounter and Region
Region PP Analysis
RV5 Placebo % Rate Redu
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Infants contributing to the analysis of hospitalizations and ED visitsa n = 14018 n = 13984
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Infants contributing to the analysis of office visits in the efficacy substudy from Finland n = 1100 n = 1171
Office visitsc 7
(4.7)
58
(37.0)
87.2
(67.5, 94
United States (including the Navajo and White Mountain Apache Nations)
Infants contributing to the analysis of hospitalizations and ED visitsa n = 12284 n = 12179
Hospitalizations & ED visitsb 3
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(84.0, 98
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Office visitsc 6
(0.8)
40
(53.5)
84.2
(66.2, 95
Latin America and the Caribbean (including Puerto Rico)
Infants contributing to the analysis of hospitalizations and ED visitsa n = 2252 n = 2237
Hospitalizations & ED visitsb 1
(0.8)
10
(8.0)
90.0
(29.4, 99
Hospitalizationsb 1
(0.8)
2
(1.6)
50.2
(<0.0, 99
ED visitsb 0
(0.0)
8
(6.4)
100
(41.2, 100
a There were 189 infants enrolled in Taiwan who were not included in the regional analyses
b The numbers in the RV5 and Placebo columns represent the number (rate) of events; the rates reflect the incidence density expressed 
c Office visits were only documented for a subset of infants from Finland and the US; there were no office visits documented in Latin Am
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Page 12 of 14able to RVGE or they did not have evaluable follow-up
time. The small differences between the G1-G4 PP analy-
sis and the MITT analysis regardless of serotype for the
overall study population appeared to be associated with
the inclusion of protocol violators in the MITT analysis
and the time needed for an immune response to develop
within the first 14 days after dose 1. There was no differ-
ence in the reduction in the rate of hospitalizations and
ED visits for the G1-G4 PP analysis and the PP analysis
regardless of serotype. High efficacy has been established
with post hoc analyses from 14 days after dose 1 until 14
days after dose 3 [27].
The consistency of the results for the PP and MITT
analyses extended to other subgroups within the study
population. The comparison of the PP and MITT analy-
ses for premature infants has already been published [28].
The reduction in the rate of hospitalizations and ED visits
was 100% (95% CI: 74.0, 100) for the G1-G4 PP analysis
and 95.5% (95% CI: 76.4, 99.9) for the MITT analysis
regardless of serotype among premature infants [28].
The higher number of healthcare encounters included
in the MITT analysis provided better precision for the
reductions in hospitalizations and ED visits combined for
each of the most prevalent serotypes circulating in the
US, Europe, and Latin America, and the broader scope of
the MITT analysis enhanced the generalizability of such
results. The rate reduction for the G2 serotype based on
the MITT analysis also provided better sensitivity to the
difference between RV5 and placebo for G2.
When the analyses were stratified by region, the rates of
healthcare utilization among infants in the placebo group
differed across geographic areas, which may be explained
by differences in healthcare systems. However, the rela-
tive effect of RV5 on reducing these rates was generally
consistent across regions based on the PP analysis [20].
The rate reductions for the U.S. and the Latin American/
Caribbean regions based on the MITT analysis regardless
of serotype were somewhat lower than the G1-G4 PP
analyses. In the US the difference in the rate reductions
for the G1-G4 PP analysis and the MITT analysis regard-
less of serotype was more pronounced for ED visits. The
rate reductions for hospitalizations were 100% (95% CI:
73.8, 100) based on the G1-G4 PP analysis compared with
97.4% (95% CI: 84.8, 99.9) based on the MITT analysis
regardless of serotype.
When the study population was stratified based on the
intensity of surveillance, the rates of healthcare encoun-
ters among infants in the placebo group differed but the
Table 6: PP Analysis for RVGE and AGE Hospitalizations and ED Visits Stratified by Intensity of Surveillance
Type of Health Care Encounter
Type of 
Site
Hospitalizations and ED visits Hospitalizations ED visits
RV5 # 
(rate)a of 
events
Placebo # 
(rate)a of 
events
% Rate 
Reduction
(95% CI)
RV5 # 
(rate)a of 
events>
Placebo # 
(rate)a of 
events
% Rate 
Reduction
(95% CI)
RV5 # 
(rate)a of 
events
Placebo # 
(rate)a of 
events
% Rate 
Reduction
(95% CI)
Sites in the Efficacy Substudy
RVGE 10
(4.3)
128
(51.8)
91.0
(81.7, 95.5)
1
(0.4)
27
(10.9)
95.7
(68.5, 99.4)
9
(3.8)
101
(40.9)
89.7
(78.1, 95.1)
AGE 280
(76.2)
483
(131.4)
39.7
(28.0, 49.5)
31
(8.4)
95
(25.8)
66.1
(48.0, 77.8)
249
(67.8)
388
(105.5)
33.2
(18.9, 45.1)
Sites not in the Efficacy Substudy
RVGE 10
(0.6)
241
(15.6)
95.9
(92.2, 97.8)
5
(0.3)
117
(7.6)
95.8
(89.6, 98.3)
5
(0.3)
124
(8.0)
96.0
(90.2, 98.4)
AGE 815
(31.6)
1385
(53.8)
41.2
(35.0, 46.8)
206
(8.0)
480
(18.7)
57.1
(49.0, 64.0)
609
(23.6)
905
(35.2)
32.8
(24.2, 40.4)
a The numbers in the RV5 and Placebo columns represent the number (rate) of events; the rates reflect the incidence density expressed as the 
annual number of events per 1000 person years
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Page 13 of 14impact of the vaccine on reducing the rates of healthcare
encounters was consistent for infants included in the
Clinical Efficacy substudy compared with other infants.
The difference in the rates of hospitalizations and ED vis-
its for RVGE based on the intensity of surveillance likely
reflects a combination of better recall of events among
parents of infants who were monitored more closely as
well as the higher proportion of stool specimens col-
lected. The efficacy of RV5 against RVGE of any severity
was also evaluated in the Clinical Efficacy substudy.
These results were reported in an earlier publication for
the PP and MITT analyses based on the G1-G4 serotypes
[10,27]. In the first rotavirus season after vaccination the
efficacy against G1-G4 RVGE regardless of severity was
74% (95% CI: 66.8, 79.9) and 60% (95% CI: 57.5, 67.1) for
the PP and MITT analyses respectively [10]. When all
RVGE regardless of serotype were included, the efficacy
was 71.8% (95% CI: 64.5, 77.8 - data not shown in tables)
and 50.9% (95% CI: 41.6, 58.9 - data not shown in tables)
for the PP and MITT analyses respectively.
Conclusion
Our analyses demonstrate the robust and consistent per-
formance of the vaccine and its relevance for infants and
young children in a prelicensure study. These findings
reflect the generalizability of the effect of RV5 on reduc-
ing RVGE including the healthcare burden associated
with serotypes not included in the vaccine and was evi-
dent when follow-up began immediately following the
first dose. Furthermore, the results did not depend on the
location of the sites or the intensity of the surveillance.
Parents of children in the Clinical Efficacy substudy were
contacted more frequently compared to other parents
and were more likely to recall events. This increased the
power of the study to detect differences between the vac-
cine and the placebo groups with a smaller sample size
but it did not influence the observed relative effect of RV5
on reducing the healthcare burden. This observation
should reassure researchers designing future clinical tri-
als for rotavirus gastroenteritis that the time interval cho-
sen to collect healthcare utilization data should not bias
the results but it may affect the power of the study.
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